MedRx Co., Ltd

4586

JP3921220004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 07:00:00 26/06/2024 BST			5-day change	1st Jan Change
171 ^JPY	-1.72%		0.00%	+13.25%

02-05	MedRx Co., Ltd announced that it has received ¥1.9076 million in funding from Evolution Capital Management LLC	CI
01-11	MedRx Co., Ltd announced that it expects to receive ¥1.9076 million in funding from Evolution Capital Management LLC	CI

MedRx Co., Ltd announced that it has received ¥9.875 million in funding from Barclays PLC Private Banking & Investment Banking Investment

April 26, 2018

On April 27, 2018, MedRx Co., Ltd (TSE:4586) closed the transaction.

Latest news about MedRx Co., Ltd

MedRx Co., Ltd announced that it has received ¥1.9076 million in funding from Evolution Capital Management LLC	02-04	CI
MedRx Co., Ltd announced that it expects to receive ¥1.9076 million in funding from Evolution Capital Management LLC	01-10	CI
MedRx Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
MedRx Co., Ltd announced that it has received ¥1.2272 million in funding from Evolution Capital Management, LLC	23/03/23	CI
MedRx Co., Ltd announced that it expects to receive ¥1.2272 million in funding from Evolution Capital Management, LLC	07/03/23	CI
MedRx Co., Ltd announced that it expects to receive ¥3.904 million in funding	21/08/22	CI
MedRx Co., Ltd announced that it has received ¥552.489 million in funding from Macquarie Bank Limited, Investment Arm	02/06/21	CI
MedRx Co., Ltd announced that it expects to receive funding from Macquarie Bank Limited, Investment Arm	17/05/21	CI
Evolution Capital Withdraws Shareholder Proposal to MedRx	31/12/20	CI
MedRx Co., Ltd announced that it has received ¥206.406 million in funding from Japan International Partners LLC	12/08/20	CI
MedRx Co., Ltd announced that it expects to receive ¥206.406 million in funding from Japan International Partners LLC	27/07/20	CI
MedRx Co., Ltd Announces Consolidated Financial Results for the Fiscal Year Ended December 31, 2019; Provides Consolidated Financial Results Forecast for the Six Months Ending June 2020 and Fiscal Year Ending December, 2020	06/02/20	CI
Evolution Capital Management Submits Shareholder Proposal to MedRx	24/12/19	CI
MedRx Co., Ltd announced that it has received ¥1.197 million in funding from Evolution Capital Management, LLC	08/12/19	CI
MedRx Co., Ltd announced that it expects to receive ¥1.197 million in funding from Evolution Capital Management, LLC	14/11/19	CI
MedRx Co. Ltd. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending December 31, 2019	07/11/19	CI
MedRx Co., Ltd Reports Consolidated Earnings Results for the Six Months Ended June 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending December 31, 2019	08/08/19	CI
MedRx Co., Ltd announced that it has received ¥99.3528 million in funding	04/03/19	CI
MedRx Co., Ltd announced that it expects to receive ¥99.3528 million in funding	11/02/19	CI
MedRx Co., Ltd Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2018; Provides Earnings Guidance for the Six Months Ending June 2018 and Year Ending December 2018	10/05/18	CI
MedRx Co., Ltd announced that it has received ¥9.875 million in funding from Barclays PLC Private Banking & Investment Banking Investment	26/04/18	CI
MedRx Co., Ltd announced that it expects to receive ¥9.875 million in funding from Barclays PLC Private Banking & Investment Banking Investment	09/04/18	CI
MedRx Co., Ltd Announces Consolidated Earnings Results for the Full Year Ended December 31, 2017; Provides Earnings Guidance for the First Half and Full Year of 2018	08/02/18	CI
Medrx Co. Ltd. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2017; Provides Earnings Guidance for the Full Year Ending December 31, 2017	09/11/17	CI
MedRx Co., Ltd Reports Consolidated Earnings Results for the Six Months Ended June 30, 2017; Provides Consolidated Earnings Guidance for the Year Ending December 2017	09/08/17	CI

Medrx Co., Ltd. is a Japan-based Company principally engaged in the research and development of pharmaceutical products. The Company produces new medicines based on percutaneous absorption formulation technology. The Company has pharmaceutical formulation technology, including percutaneous absorbent technology of ionic liquid transdermal system (ILTS) using characteristics of ionic liquid, and percutaneous absorbent technology of nano-sized colloid transdermal system (NCTS) using Nano colloidization technology of drug. Based on the technology, The Company aims to maximize drug efficacy, reduce side effects, prevent forgetting to drink, and to administer to patients who are difficult to orally administer, and to produce medicines with new added value.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
MEDRX CO., LTD	+13.25%	47.87M
KYOWA KIRIN CO. LTD.	+17.03%	9.11B
SK BIOPHARMACEUTICALS CO., LTD.	-24.00%	4.44B
YUHAN CORPORATION	+13.37%	4.24B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+31.17%	4.03B
INDIVIOR PLC	+7.68%	2.14B
BETTA PHARMACEUTICALS CO., LTD.	-34.04%	1.9B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+7.56%	1.94B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-47.93%	1.63B

Specialty & Advanced Pharmaceuticals

MedRx Co., Ltd

Equities

4586

JP3921220004

Pharmaceuticals

MedRx Co., Ltd announced that it has received ¥9.875 million in funding from Barclays PLC Private Banking & Investment Banking Investment

Latest news about MedRx Co., Ltd

Chart MedRx Co., Ltd

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals